BrainStorm CEO Lands 1.8 Million RSUs at Zero Cost as Executives Bulk Up Holdings Amid Quiet Insider Buying Surge

Insider Confidence Grows Amid New RSU Award

BrainStorm Cell Therapeutics Inc. (OTC: BCTI) announced a significant insider transaction on February 26, 2026, when President & CEO Chaim Lebovits accepted 1,800,000 restricted stock units (RSUs) at no cost. The award, granted under the company’s RSU plan, vests 50 % immediately and the balance at the six‑month anniversary, contingent on continued employment. With the transaction, Lebovits’ post‑deal holding rises to just over 2 million shares—more than a 10 % increase from his prior position. The deal was executed at the current market price of $0.75, reflecting the board’s confidence that the company’s long‑term prospects will justify the dilution.

A Quiet Surge in Executive Activity

The RSU award sits alongside a broader wave of insider buying that hit the market on the same day. Senior executives—including EVP Uri Yablonka, Chief Business Officer, and other officers such as Patlis Alla and Jacob Fränkel—each purchased 100,000–200,000 shares at zero price, boosting their post‑transaction holdings to the 140,000‑260,000‑share range. In addition, several employees acquired stock options for 150,000–225,000 shares at $0.70 each, signaling a robust belief in the company’s future. The collective activity suggests that insiders are positioning themselves to share in any upside that may come from the company’s ongoing clinical milestones and potential funding rounds.

Implications for Investors

For the market, the insider buying trend is a positive signal. It demonstrates that those with the most intimate knowledge of BrainStorm’s science and strategy are willing to invest personally, which often correlates with confidence in the company’s trajectory. The RSU award, in particular, aligns the CEO’s incentives with shareholder value, as the units vest over time and are subject to performance thresholds tied to the company’s regulatory and financial milestones.

From a valuation standpoint, the stock’s recent 10 % weekly gain and 11.9 % monthly rise may reflect short‑term optimism, but the year‑to‑date decline of 32 % and a negative P/E ratio underscore that the company remains a speculative play. Investors should weigh the insider activity against the company’s still‑nascent product pipeline and the competitive landscape of neurodegenerative therapeutics. If the Phase 3b ALS trial of NurOwn® delivers positive data, the market could reward the stock more substantially, validating the insiders’ bullish stance.

Looking Ahead

The infusion of insider confidence arrives just as BrainStorm’s board expands with regulatory veteran Peter Pitts, positioning the company for a critical Phase 3b trial and potential funding. If these milestones are achieved, the stock could see renewed momentum, and the insider holdings—now more substantial—will likely translate into tangible shareholder gains. For investors, the current insider transactions represent a useful barometer: strong insider buying in a biotech that is still awaiting clinical confirmation typically signals that insiders anticipate a significant upside. The next few quarters, therefore, will be decisive in determining whether BrainStorm can translate this optimism into tangible progress and market performance.